Dry Age-Related Macular Degeneration – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

  • Published Date : September 12, 2026
  • Updated On : November 6, 2026
  • Pages : 154

Dry Age-Related Macular Degeneration Market Outlook and Forecast

Thelansis’s “Dry Age-Related Macular Degeneration Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dry Age-Related Macular Degeneration treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dry Age-Related Macular Degeneration Overview

Dry age-related macular degeneration (AMD) is a retinal disease marked by drusen and damage to the retinal pigment epithelium and photoreceptors. Early disease is often asymptomatic; later stages can blur central vision and impair reading. Some cases advance to geographic atrophy (GA), causing permanent central vision loss when the fovea is involved. Risk rises with age, genetics and smoking; complement dysregulation contributes to disease biology. Care includes smoking cessation and retinal monitoring. AREDS2 supplements may slow progression in eligible patients with intermediate AMD or reduce fellow-eye risk when late AMD affects one eye. For GA, intravitreal pegcetacoplan or avacincaptad pegol can slow lesion growth but cannot restore lost vision. Repeated injections carry risks, including neovascular AMD and ocular inflammation; retinal vasculitis or vascular occlusion has also been reported with pegcetacoplan. Gene, cell-replacement and neuroprotective approaches remain investigational.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2026–2036)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…
 

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)

Frequently asked questions